Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Berry Oncology

Request full access

Genomic testing and early screening for cancer

Fuzhou City, ChinaFounded 2017Biotech & Life Sciences

About Berry Oncology

Berry Oncology, established in 2017 as a subsidiary of Berry Genomics, is a company focused on cancer diagnostics through genomic testing. The company's stated mission is to “diagnose all cancers early, treat all patients precisely”. Its offerings span genetic susceptibility analysis, early cancer screening, companion diagnostics for targeted and immune therapies, and treatment response monitoring.

The company's core technology is its HIFI platform, which utilizes liquid biopsy and multi-omics based on next-generation sequencing (NGS) to detect cancer signals. One of their key products is the "HIFI Pan-Cancer Screening," designed to detect six high-incidence cancers in China: lung, esophageal, gastric, liver, pancreatic, and colorectal cancer. This product analyzes cell-free DNA (cfDNA) through whole-genome sequencing (WGS). The company has reported a sensitivity of 87.58% and a specificity of 99.09% for this multi-cancer screening product. In 2020, Berry Oncology launched an early screening product for liver cancer named “Lai Si Ning”.

Led by CEO Jun Zhou, Berry Oncology has focused its product design on the specific tumorigenic characteristics of the Chinese population. The company has engaged in strategic partnerships to expand its reach. In 2021, it partnered with Alibaba Health to build a comprehensive cancer screening and prevention ecosystem, combining internet services with its early screening technology. The company has also collaborated with MGI Tech to enhance the commercialization and cost-effectiveness of its early cancer screening products. To support its research and product development, Berry Oncology has secured significant funding, including a Series B1 round of nearly $100 million in 2021.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
24.7/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Oncology, Biomarkers, Genetics and genomics, Health Diagnostics, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2021 $99M $397M Legend Capital · Qiming Venture Partners · E-Fund · Zhongjin Qichen Industry Equity Investment Fund —
SERIES AOther financing Mar 2020 $9.6M $39M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Berry Oncology website traffic

Latest recorded traffic for Berry Oncology is 180 monthly website visits, up 1700% over the last three months.

Latest monthly visits180 3-month web change+1700%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Berry Oncology in the Fuzhou City ecosystem

Live from Dealroom

The Berry Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Qiming Venture Partners
  • Boyu Capital
  • China Merchants Capital
  • Legend Capital
  • E-Fund
  • Zhongjin Qichen Industry Equity Investment Fund
  • Fujian Venture Investment Management
  • Xiamen C&D Emerging Industry Equity Investment
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Fuzhou City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Berry Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Berry Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.